Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

148 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Developmental and pathological angiogenesis.
Chung AS, Ferrara N. Chung AS, et al. Annu Rev Cell Dev Biol. 2011;27:563-84. doi: 10.1146/annurev-cellbio-092910-154002. Epub 2011 Jul 13. Annu Rev Cell Dev Biol. 2011. PMID: 21756109 Review.
We also discuss current knowledge of physiological angiogenic processes as well as their disruptions in pathological processes, particularly tumorigenesis....
We also discuss current knowledge of physiological angiogenic processes as well as their disruptions in pathological processes …
Phosphoproteomic analysis implicates the mTORC2-FoxO1 axis in VEGF signaling and feedback activation of receptor tyrosine kinases.
Zhuang G, Yu K, Jiang Z, Chung A, Yao J, Ha C, Toy K, Soriano R, Haley B, Blackwood E, Sampath D, Bais C, Lill JR, Ferrara N. Zhuang G, et al. Sci Signal. 2013 Apr 16;6(271):ra25. doi: 10.1126/scisignal.2003572. Sci Signal. 2013. PMID: 23592840
The PI3K (phosphatidylinositol 3-kinase)-mTORC2 (mammalian target of rapamycin complex 2) axis emerged as central in activating VEGF-regulated phosphorylation and increasing endothelial cell viability by suppressing the activity of the transcription factor FoxO1 (forkhead …
The PI3K (phosphatidylinositol 3-kinase)-mTORC2 (mammalian target of rapamycin complex 2) axis emerged as central in activating VEGF- …
An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy.
Chung AS, Wu X, Zhuang G, Ngu H, Kasman I, Zhang J, Vernes JM, Jiang Z, Meng YG, Peale FV, Ouyang W, Ferrara N. Chung AS, et al. Nat Med. 2013 Sep;19(9):1114-23. doi: 10.1038/nm.3291. Epub 2013 Aug 4. Nat Med. 2013. PMID: 23913124
Although angiogenesis inhibitors have provided substantial clinical benefit as cancer therapeutics, their use is limited by resistance to their therapeutic effects. ...
Although angiogenesis inhibitors have provided substantial clinical benefit as cancer therapeutics, their use is limited by resistanc …
Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies.
Brauer MJ, Zhuang G, Schmidt M, Yao J, Wu X, Kaminker JS, Jurinka SS, Kolumam G, Chung AS, Jubb A, Modrusan Z, Ozawa T, James CD, Phillips H, Haley B, Tam RN, Clermont AC, Cheng JH, Yang SX, Swain SM, Chen D, Scherer SJ, Koeppen H, Yeh RF, Yue P, Stephan JP, Hegde P, Ferrara N, Singh M, Bais C. Brauer MJ, et al. Clin Cancer Res. 2013 Jul 1;19(13):3681-92. doi: 10.1158/1078-0432.CCR-12-3635. Epub 2013 May 17. Clin Cancer Res. 2013. PMID: 23685835
The potential value of VDV genes as candidate predictive biomarkers was tested by correlating high or low VDV gene expression levels in pretreatment clinical samples with the subsequent clinical efficacy of bevacizumab (anti-VEGF)-containing therapy. ...We propose that VDV …
The potential value of VDV genes as candidate predictive biomarkers was tested by correlating high or low VDV gene expression levels …
Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment.
Phan VT, Wu X, Cheng JH, Sheng RX, Chung AS, Zhuang G, Tran C, Song Q, Kowanetz M, Sambrone A, Tan M, Meng YG, Jackson EL, Peale FV, Junttila MR, Ferrara N. Phan VT, et al. Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6079-84. doi: 10.1073/pnas.1303302110. Epub 2013 Mar 25. Proc Natl Acad Sci U S A. 2013. PMID: 23530240 Free PMC article.
Targeting the tumour vasculature: insights from physiological angiogenesis.
Chung AS, Lee J, Ferrara N. Chung AS, et al. Nat Rev Cancer. 2010 Jul;10(7):505-14. doi: 10.1038/nrc2868. Nat Rev Cancer. 2010. PMID: 20574450 Review.
Angiogenesis is active only under specific physiological conditions in healthy adults but the vasculature can be aberrantly activated to generate new blood vessels during pathological conditions such as cancer and chronic inflammation. ...
Angiogenesis is active only under specific physiological conditions in healthy adults but the vasculature can be aberrantly activated to gen …
Targeting the tumor microenvironment with SRC kinase inhibition.
Chung AS, Ferrara N. Chung AS, et al. Clin Cancer Res. 2010 Feb 1;16(3):775-7. doi: 10.1158/1078-0432.CCR-09-3081. Epub 2010 Jan 26. Clin Cancer Res. 2010. PMID: 20103657
[No authors listed] [No authors listed] PMID: 27630764
Systems analysis of the prostate tumor suppressor NKX3.1 supports roles in DNA repair and luminal cell differentiation.
Yang CC, Chung A, Ku CY, Brill LM, Williams R, Wolf DA. Yang CC, et al. F1000Res. 2014 May 21;3:115. doi: 10.12688/f1000research.3818.2. eCollection 2014. F1000Res. 2014. PMID: 25177484 Free PMC article.
NKX3.1 is a homeobox transcription factor whose function as a prostate tumor suppressor remains insufficiently understood because neither the transcriptional program governed by NKX3.1, nor its interacting proteins have been fully revealed. ...
NKX3.1 is a homeobox transcription factor whose function as a prostate tumor suppressor remains insufficiently understood because nei …
148 results
Jump to page
Feedback